Search

Savara Inc

Fechado

SetorSaúde

4.75 -0.21

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.74

Máximo

5.01

Indicadores-chave

By Trading Economics

Rendimento

-2.9M

-40M

EPS

-0.16

Funcionários

70

EBITDA

-2.9M

-40M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+131.4% upside

Dividendos

By Acuity

Próximos Ganhos

10 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-182M

992M

Abertura anterior

4.96

Fecho anterior

4.75

Savara Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de out. de 2026, 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

12 de out. de 2026, 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

9 de out. de 2026, 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

8 de out. de 2026, 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

7 de out. de 2026, 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

6 de out. de 2026, 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2 de out. de 2026, 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

1 de out. de 2026, 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

30 de set. de 2026, 21:03 UTC

Social Media

Savara Inc shares are trading higher in after-market hours amid speculation of a short squeeze ahead of its PDUFA date for molgramostim, with a market cap of $1 billion.

28 de set. de 2026, 20:02 UTC

Social Media

Savara Inc is trading higher amid notable social media activity and unusual options bets, with a PDUFA date set for November 22.

25 de set. de 2026, 20:07 UTC

Savara Inc shares fell sharply, continuing the downward trend with a cumulative return in negative territory and remaining below its 20-day moving average.

24 de set. de 2026, 19:46 UTC

Savara Inc is trading higher, having previously peaked before a slight retracement, though it remains below its 20-day moving average.

23 de set. de 2026, 22:01 UTC

Savara Inc gained in after-market trading following a brief decline earlier in the session, though it remains below its 20-day moving average.

22 de set. de 2026, 20:05 UTC

Savara Inc's stock is declining sharply, moving from an initial gain to a notable drop, trading below its 20-day moving average.

21 de set. de 2026, 20:12 UTC

Savara Inc is advancing in after-market trading, positioned above its 20-day moving average and near the upper end of its one-month range.

18 de set. de 2026, 23:11 UTC

Savara Inc is trading modestly higher in after-market hours, reflecting the broader market's upward movement, with notable gains since Friday's close.

17 de set. de 2026, 23:11 UTC

Savara Inc is seeing a modest upward move in after-market trading, currently near the upper end of its one-month range.

16 de set. de 2026, 20:10 UTC

Savara Inc shares fell sharply today, continuing a decline since Tuesday and trading significantly below its 20-day moving average.

15 de set. de 2026, 20:07 UTC

Savara Inc shares are lower, impacted by a sharp decline in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

11 de set. de 2026, 20:08 UTC

Savara Inc. shares are trading lower today, continuing a decline since Thursday's close amid a broader market downturn.

10 de set. de 2026, 20:03 UTC

Savara Inc. shares are lower today, reflecting broader market conditions amid the European Central Bank's recent interest rate hike and inflation projections.

4 de set. de 2026, 19:26 UTC

Savara Inc shares are higher today, trading within a narrow range. The stock is currently near the lower end of its one-month range.

3 de set. de 2026, 20:02 UTC

Savara Inc shares are lower during Thursday's session, retracing from an earlier peak amid rising jobless claims that may affect Federal Reserve policy.

2 de set. de 2026, 20:08 UTC

Savara Inc. shares are higher today, driven by a significant upward trend in the Biotechnology sub-sector. No specific company news was identified.

1 de set. de 2026, 19:36 UTC

Savara Inc. shares are lower today, continuing a decline since Monday. The stock remains below its 20-day moving average amid rising inflation concerns.

31 de ago. de 2026, 22:01 UTC

Savara Inc. shares rose in after-market trading, advancing since Monday's close, despite earlier pulling back from a session high. No specific news was identified.

28 de ago. de 2026, 21:02 UTC

In after-market trading, Savara Inc. has increased following a flat start, indicating upward momentum despite remaining below its 20-day moving average.

27 de ago. de 2026, 23:56 UTC

Savara Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment remains mixed amid ongoing inflation concerns and upcoming Fed guidance.

25 de ago. de 2026, 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

24 de ago. de 2026, 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

Comparação entre Pares

Variação de preço

Savara Inc Previsão

Preço-alvo

By TipRanks

131.4% parte superior

Previsão para 12 meses

Média 11.2 USD  131.4%

Máximo 16 USD

Mínimo 9 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Savara Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat